Physician profile
Daniel Lembo
NPI 1497463152
$2,055.31
in general payments reported to CMS, 2019-2025
21 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $161 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $461.99 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $363.17 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $306.86 | 2025 | |
| Astellas Pharma US INC | $167.38 | 2024-2025 | Veozah |
| Pfizer INC. | $141.96 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.71 | 2025 | Caplyta |
| Lilly USA, LLC | $93.20 | 2025 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $56.74 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $43.96 | 2025 | Shingrix |
| Lundbeck LLC | $39.89 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.72 | 2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $35.42 | 2025 | Zoryve |
| Exact Sciences Corporation | $27.16 | 2025 | The Cologuard Plus Collection Kit |
| Actelion Pharmaceuticals US, INC. | $25.75 | 2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $23.86 | 2025 | Rotateq, Capvaxive, Gardasil 9 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $22.59 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.36 | 2025 | Xifaxan |
| Scpharmaceuticals INC. | $15.96 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.78 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.64 | 2025 | Quviviq |
| Currax Pharmaceuticals LLC | $14.21 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lembo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.